Snakebite deaths reach up to 513,000 a year, new global model shows

Snake envenoming kills between 274,000 and 513,000 people every year, according to a new global burden study that suggests official statistics miss most of the true toll. The same analysis estimates that at least 2.1 million people suffer envenoming annually, with the real figure possibly as high as 7 million, and that more than 800,000 survivors are left with long-term disabilities each year.

For anyone in clinical or public-health practice, the numbers demand attention. Snakebite has long sat at the margins of global health reporting. This study, published by researchers with decades of combined experience in snakebite and tropical disease epidemiology, argues the problem is a public health crisis on a far greater scale than national records show.

How the study was built

The researchers reviewed data from 79 countries, drawing on studies published up to March 31, 2025. The work updates their milestone 2008 global burden study. Because more than half of the countries where venomous snakes pose a threat keep no count of bites or envenomings, the team built a geostatistical model to fill the gaps.

The model works by combining known data points with environmental and socioeconomic signals, including climate, snake species richness and socioeconomic indicators. Instead of assuming values for every region, it uses statistical probability to calculate a range of likely outcomes, even where official health records are completely blank. By comparing hospital-reported data and regional statistics against community-survey data, the framework accounts for unreported cases and produces both a baseline floor and a potential upper ceiling for envenomings and deaths.

That method matters. In rural sub-Saharan Africa and south Asia, many victims live hours from the nearest clinic, lack transport, or seek care from traditional healers, so their cases never enter national health statistics. The takeaway: raw surveillance data alone cannot describe this disease burden.

Why sub-Saharan Africa carries 45% of the burden

The geography of the crisis is sharply uneven. Sub-Saharan Africa alone accounts for 45% of all global envenomings and fatalities, a burden the authors say has likely been underestimated for decades. People in the region experience snake envenoming and death at nearly three times the rate seen in south Asia. Nigeria, the Democratic Republic of Congo and Ethiopia face the heaviest burden, driven by dense rural populations and high exposure in agricultural fields.

The reasons are structural rather than accidental. The continent hosts a rich diversity of medically important venomous species:

• Saw-scaled vipers (Echis spp.)
• Puff adders (Bitis arietans)
• African cobras (Naja spp.)
• Mambas (Dendroaspis spp.)

These species cause substantial morbidity and mortality across the continent. Millions of rural agricultural workers labor in open fields without protective boots and walk unlit footpaths at night. When a bite occurs, fragile health systems, long travel distances to regional facilities, and the high cost or total absence of effective antivenom mean a treatable emergency can quickly become fatal. Similar conditions exist in parts of Asia.

The disability toll compounds the economic one. The study estimates over 800,000 survivors are left with long-term physical disabilities each year, including amputations and other permanent impairments. These injuries reduce household income, raise healthcare costs and push already vulnerable farming families deeper into poverty.

What changes for practice and policy?

The World Health Organization has set a target to halve snakebite mortality and disability by 2030. The authors argue that country-level mapping of the problem is the first crucial step toward that goal, and that meeting it requires moving away from guesswork toward spatial risk data guiding real-world policy.

Their recommendations are concrete:

• Strategically stockpile antivenom in identified high-risk hotspots
• Train primary healthcare workers in high-burden rural zones
• Improve rapid transport infrastructure for bite victims

The public-health implication is distinct from any single clinical intervention. Better data cannot solve snakebite on its own, the authors note, but it can help ensure that antivenom, healthcare services and prevention efforts reach the communities that need them most. For practitioners and health planners in endemic regions, the study's hotspot maps offer a practical tool for deciding where limited antivenom supplies and training budgets will do the most good before the WHO's 2030 deadline arrives.